Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07594717 · ClinicalTrials.gov registry record
Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder
A clinical trial, sponsored by Prisma Health-Upstate.
- Recruiting
- Registry status
- 70
- Enrollment target
NCT07594717: Recruiting study, sponsored by Prisma Health-Upstate.
NCT07594717 is a clinical trial that is actively recruiting participants, run by Prisma Health-Upstate. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07594717 is actively recruiting participants, sponsored by Prisma Health-Upstate.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
Study Summary
This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers will examine how different flavor profiles influence the appeal and reinforcing effects of ECs in this population. The goal is to identify EC flavors that may enhance the acceptability of ECs as a potential harm-reduction strategy among adults with OUD receiving buprenorphine treatment.
Primary Outcome
Perceived sweetness of each e-cigarette flavor will be assessed using a one-item VAS ranging from "Not sweet at all" to "Extremely sweet," with higher scores indicating greater perceived sweetness.
Interventions
- DRUG Sweet-cooling
- DRUG Sweet non-cooling EC flavor
- DRUG Tobacco flavor EC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2026-05 |
What NCT07594717 shows while recruiting
NCT07594717 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Sweet-cooling is the first listed.
NCT07594717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07594717 about?
NCT07594717 is a clinical study titled "Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder". This study examines the effects of e-cigarette (EC) flavors among adults with opioid use disorder (OUD) receiving buprenorphine treatment who currently use e-cigarettes. Participants will smell and rate 11 EC flavors based on appeal, sensory characteristics, and likelihood of future use. Researchers...
What is the current status of trial NCT07594717?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2025-11-12. Estimated completion is 2026-05.
What interventions are being tested in trial NCT07594717?
The interventions under investigation include: Sweet-cooling (DRUG), Sweet non-cooling EC flavor (DRUG), Tobacco flavor EC (DRUG).
Who is sponsoring clinical trial NCT07594717?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI